187 related articles for article (PubMed ID: 17851876)
1. Deafness associated with the use of Bortezomib in multiple myeloma.
Chim CS; Wong LG
Acta Oncol; 2008; 47(2):323-4. PubMed ID: 17851876
[No Abstract] [Full Text] [Related]
2. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
Fang B; Song Y; Ma J; Zhao RC
Acta Haematol; 2007; 118(2):65-7. PubMed ID: 17505132
[No Abstract] [Full Text] [Related]
3. The impact of bortezomib on the risk of thrombosis in multiple myeloma.
Connolly G
Leuk Res; 2011 Feb; 35(2):145-6. PubMed ID: 20952063
[No Abstract] [Full Text] [Related]
4. Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug.
Duek A; Feldberg E; Haran M; Berrebi A
Am J Hematol; 2007 Jun; 82(6):502-3. PubMed ID: 17301973
[No Abstract] [Full Text] [Related]
5. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
6. Severe pulmonary complications after bortezomib treatment in multiple myeloma.
Dun X; Yuan Z; Fu W; Zhang C; Hou J
Hematol Oncol; 2010 Mar; 28(1):49-52. PubMed ID: 19728395
[No Abstract] [Full Text] [Related]
7. Hyperlipidemia in a myeloma patient after bortezomib treatment.
Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
[No Abstract] [Full Text] [Related]
8. Bortezomib-induced acute pancreatitis.
Elouni B; Ben Salem C; Zamy M; Sakhri J; Bouraoui K; Biour M
JOP; 2010 May; 11(3):275-6. PubMed ID: 20442528
[No Abstract] [Full Text] [Related]
9. Bortezomib increases survival of patients with relapsed multiple myeloma.
Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
[No Abstract] [Full Text] [Related]
10. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.
Yokose N; Hirakawa T; Inokuchi K
Leuk Res; 2009 Aug; 33(8):e106. PubMed ID: 19285724
[No Abstract] [Full Text] [Related]
11. Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
Moon SJ; Min CK; Lee DG; Lee S; Lee JW; Min WS; Kim CC; Kim M; Park G; Kim Y
Acta Haematol; 2007; 117(4):211-4. PubMed ID: 17237615
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-induced Sweet syndrome.
Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
[No Abstract] [Full Text] [Related]
13. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
Pitini V; Arrigo C; Altavilla G; Naro C
Leuk Res; 2007 Jul; 31(7):1027-8. PubMed ID: 17134751
[No Abstract] [Full Text] [Related]
14. Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance.
Foley PW; Hamilton MS; Leyva F
J Cardiovasc Med (Hagerstown); 2010 May; 11(5):386-8. PubMed ID: 19584744
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B.
Goldberg R; Smith E; Bell S; Thompson A; Desmond PV
Intern Med J; 2013 Jul; 43(7):835-6. PubMed ID: 23841765
[No Abstract] [Full Text] [Related]
16. Multiple myeloma associated with porphyria cutanea tarda: a possible role of bortezomib?
Cabanillas M; Peteiro C; Toribio J
Dermatology; 2006; 213(3):246-7. PubMed ID: 17033179
[No Abstract] [Full Text] [Related]
17. Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib.
Dehesa L; Bastida J; Limeres-González M; Campos-Adsuar C; Gómez-Duaso J
Clin Exp Dermatol; 2009 Dec; 34(8):e1031-2. PubMed ID: 20055832
[No Abstract] [Full Text] [Related]
18. Bortezomib-induced skin eruption.
Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
[TBL] [Abstract][Full Text] [Related]
19. Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.
Aguayo-Leiva I; Vano-Galvan S; Carrillo-Gijon R; Jaén-Olasolo P
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1363-4. PubMed ID: 20337821
[No Abstract] [Full Text] [Related]
20. Late onset of bortezomib-associated cutaneous reaction following herpes zoster.
Varettoni M; Vassallo C; Borroni G; Mangiacavalli S; Zappasodi P; Rosso R; Lazzarino M; Corso A
Ann Hematol; 2007 Apr; 86(4):301-2. PubMed ID: 17131123
[No Abstract] [Full Text] [Related]
[Next] [New Search]
